達意隆(002209.SZ):全資子公司獲得《化粧品生產許可證》
格隆匯 7 月 21日丨達意隆(002209.SZ)公告,公司於2020年7月20日收到全資子公司天津寶隆包裝技術開發有限公司的通知,其獲得了天津市藥品監督管理局頒發的《化粧品生產許可證》,具體如下:
企業名稱:天津寶隆包裝技術開發有限公司
許可證編號:津粧20200003
許可項目:一般液態單元(啫喱類、護髮清潔類、護膚水類);膏霜乳液單元(護髮類、護膚清潔類)
企業住所:天津市西青經濟技術開發區天源道9號A1、A2、B1座
生產地址:天津市西青經濟技術開發區天源道9號A1、A2、B1座
法定代表人:張頌明
發證機關:天津市藥品監督管理局
有效期限至:2025年7月2日
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.